Edition:
United Kingdom

Jaguar Health Inc (JAGX.OQ)

JAGX.OQ on NASDAQ Stock Exchange Capital Market

0.13USD
14 Dec 2017
Change (% chg)

$0.01 (+5.52%)
Prev Close
$0.12
Open
$0.13
Day's High
$0.17
Day's Low
$0.12
Volume
1,389,476
Avg. Vol
372,181
52-wk High
$1.52
52-wk Low
$0.11

Summary

Name Age Since Current Position

James Bochnowski

71 2014 Chairman of the Board

Lisa Conte

58 2013 President, Chief Executive Officer, Director

Karen Wright

2015 Chief Financial Officer

Steven King

59 2014 Executive Vice President - Sustainable Supply, Ethnobotanical Research and Intellectual Property and Secretary

Roger Waltzman

2017 Executive Officer

Ari Azhir

69 2016 Director

Folkert Kamphuis

56 2015 Director

John Micek

63 2016 Director

Jiahao Qiu

30 2014 Director

Zhi Yang

58 2014 Director

Biographies

Name Description

James Bochnowski

Mr. James J. Bochnowski is the Chairman of the Board of Jaguar Animal Health Inc., since June 2014. Since 1988, Mr. Bochnowski has served as the founder and Managing Member of Delphi Ventures, a venture capital firm. In 1993, Mr. Bochnowski co-founded Technology Venture Investors. Mr. Bochnowski holds an M.B.A. from Harvard University Graduate School of Business and a B.S. in Aeronautics and Astronautics from Massachusetts Institute of Technology.

Lisa Conte

Ms. Lisa A. Conte is the President, Chief Executive Officer, Director of Jaguar Animal Health Inc., since she founded the company in June 2013. From 2001 to 2014, Ms. Conte served as the Chief Executive Officer of Napo Pharmaceuticals, Inc., a biopharmaceutical company she founded in November 2001. In 1989, Ms. Conte founded Shaman Pharmaceuticals, Inc., a natural product pharmaceutical company, which declared bankruptcy in 2001. Additionally, Ms. Conte is Napo Pharmaceutical's current Interim Chief Executive Officer and has served as a member of its board of directors since 2001. Ms. Conte is also currently a member of the board of directors of Healing Forest Conservatory, a California not-for-profit public benefit corporation. Ms. Conte holds an M.S. in Physiology and Pharmacology from the University of California, San Diego, and an M.B.A. and A.B. in Biochemistry from Dartmouth College.

Karen Wright

Ms. Karen S. Wright is the Chief Financial Officer of the company. She brings more than 30 years of financial experience with a number of international biotech companies. Wright was most recently head of finance for Clene Nanomedicine. She also served as vice president of finance and corporate controller at multiple other private and public companies, including Veracyte (NasdaqGM: VCYT) and Intermune, which was acquired by Roche. Early in her career, Wright spent 13 years at Genentech building a strong foundation in the biotech industry.

Steven King

Dr. Steven R. King, Ph.D., is the Executive Vice President - Sustainable Supply, Ethnobotanical Research and Intellectual Property and Secretary of Jaguar Animal Health Inc., since September 2014. From 2002 to 2014, Dr. King served as the Senior Vice President of Sustainable Supply, Ethnobotanical Research and Intellectual Property at Napo Pharmaceuticals, Inc. Prior to that, Dr. King served as the Vice President of Ethnobotany and Conservation at Shaman Pharmaceuticals, Inc. Dr. King has been recognized by the International Natural Products and Conservation Community for the creation and dissemination of research on the long-term sustainable harvest and management of Croton lechleri, the widespread source of crofelemer. Dr. King is currently a member of the board of directors of Healing Forest Conservatory, a California not-for-profit public benefit corporation. King holds a Ph.D. in Biology from the Institute of Economic Botany of the New York Botanical Garden and an M.S. in Biology from the City University of New York.

Roger Waltzman

Ari Azhir

Dr. Ari Azhir, PhD., is the Director of the Company. Dr. Azhir is an entrepreneur and founder and CEO of two companies focused on central nervous system (CNS) therapeutics: Neuraltus Pharmaceuticals and Neurocea LLC. She has broad experience launching and building life science companies and has successfully commercialized and brought more than 20 healthcare products to market, ranging from small molecule pharmaceuticals for CNS and dermatology to disruptive technologies in medical devices. These technologies include flow cytometry products at Becton Dickinson and ultrasound devices at Accuson, where she held executive management positions. Dr. Azhir has wide-ranging drug development experience and has filed an NDA and gained approval for Luxiq®, a drug that has been successfully commercialized. She also has extensive experience building strong patent portfolios and is the key inventor and patent holder of 12 patents. She serves on the translational research board of UCSF and has served on private boards (Polar Springs and Neuraltus), as well as nonprofit boards (The Hearing Society and American Women in Science). Dr. Azhir received her B.SC in Biochemistry and Mathematics, as well as her M.Ph. in Biophysics, from Kings’ College, London University, and received a PhD. in Biophysics from Tehran University.

Folkert Kamphuis

Mr. Folkert W. Kamphuis is the Director of the Company. Mr. Kamphuis currently has his own consulting business. He most recently served as Global Head of Strategic Planning at Novartis Animal Health, the former animal health unit of Swiss pharmaceutical giant Novartis, a role in which he oversaw business development and licensing, portfolio and salesforce development, and was a member of Novartis’s Animal Health Executive Committee, until its acquisition by Elanco. Mr Kamphuis joined Novartis Animal Health in 2009, and from 2012 to 2014 served as General Manager North America and as Chief Operating Officer from 2009 to 2012. Prior thereto, Mr. Kamphuis spent 20 years in various executive, business development and global marketing roles at Pfizer Animal Health/Pharmacia and Merial/Merck Sharp & Dohme in different roles. Mr. Kamphuis received a B.A. in Marketing equivalent degree (VWO-b) from the Dutch Institute of Marketing, Drachten, the Netherlands, and an MSc in Animal Nutrition from the Wageningen University and Research Center, Wageningen, the Netherlands. Mr. Kamphuis’ extensive experience and education in the animal health sector led the Board to conclude that he is qualified to serve as a director of the Company.

John Micek

Mr. John J. Micek, III J.D. is the Director of the Company. From 2000 to 2010, Mr. Micek was managing director of Silicon Prairie Partners, LP, a Palo Alto, California based family-owned venture fund. Since 2010, Mr. Micek has been managing partner of Verdant Ventures, a merchant bank dedicated to sourcing and funding university and corporate lab spinouts in areas including pharmaceuticals and cleantech. Mr. Micek serves on the board of directors of Armanino Foods of Distinction, Innovaro Corporation and JAL/Universal Assurors. He is also a board member and CEO and CFO of Enova Systems, and from March 2014 to August 2015 he served as interim CFO for Smith Electric Vehicles Inc. From 2000 to 2003, he was on the board of directors of Universal Warranty Corporation, a wholly-owned subsidiary of GMACI (a General Motors subsidiary). Mr. Micek is a cum laude graduate of Santa Clara University, and the University of San Francisco School of Law, and is a practicing California attorney specializing in financial services. Additionally, he was an adjunct faculty professor in Corporate Governance and Ethics at the graduate school of Economics at the University of San Francisco in 2013 and 2014. Mr. Micek’s extensive experience with venture capital backed healthcare companies and experience as both an executive officer and member of the board of directors of numerous companies led the Board to conclude that he is qualified to serve as a director of the Company.

Jiahao Qiu

Mr. Jiahao Qiu is the Director of Jaguar Animal Health Inc., since February 2014. Since 2010, Mr. Qiu has served as a Principal of BioVeda Management, Ltd., a life science investment firm. From 2009 to 2010, he served as an interpreter for the Delegation of the European Union to China. Mr. Qiu holds a B.S. in Biotechnology from the Jiao Tong University in Shanghai, China.

Zhi Yang

Mr. Zhi Yang, Ph.D. is the Director of Jaguar Animal Health Inc., Dr. Yang has served as the Chairman, Managing Partner and Founder of BioVeda Management, Ltd., a life science investment firm. Dr. Yang is currently an advisor to the China Health and Medical Development Foundation, under China's Ministry of Health. Dr. Yang holds a Ph.D. in Molecular Biology and Biochemistry, as well as an M.A. in Cellular and Developmental Biology, both from Harvard University.